ABUS
Arbutus Biopharma Corporation
ABUS's fundamentals are strong: revenue grew more than tenfold and its operating margin went from −320% to 81%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ABUS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Unavailable |
ABUS's revenue, profitability and cash flow are currently healthy. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ABUS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 3.6x | $4.03 | — |
| Cheap | 5.2x | $5.83 | +45% |
| Fair | 5.5x | $6.20 | +54% |
| Expensive | 6.3x | $7.07 | +75% |
Historical ranges are pointers, not guarantees.
ABUS's PE is 3.6x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ABUS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ABUS's losses to shrink, with revenue growing.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ABUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.13 | +$1.36 |
| Q2 2026 | $0.79 | +$1.08 |
| Q1 2026 | $0.83 | +$1.24 |
| Q4 2025 | -$0.17 | +$0.21 |
| Q3 2025 | -$0.23 | +$0.20 |
| Q2 2025 | -$0.29 | +$0.16 |
| Q1 2025 | -$0.41 | +$0.03 |
| Q4 2024 | -$0.38 | +$0.06 |
ABUS has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ABUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $299K | -43% |
| Q2 2026 | $1M | -91% |
| Q1 2026 | $179.1M | +10055% |
| Q4 2025 | $1.1M | -33% |
| Q3 2025 | $529K | -60% |
| Q2 2025 | $10.7M | +522% |
| Q1 2025 | $1.8M | +15% |
| Q4 2024 | $1.6M | -27% |
ABUS's revenue is growing: $299,000 last quarter, down 43% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3510% | -1873 points |
| Q2 2026 | -588% | -602 points |
| Q1 2026 | 94% | +1551 points |
| Q4 2025 | -503% | +382 points |
| Q3 2025 | -1637% | -36 points |
| Q2 2025 | 14% | +1264 points |
| Q1 2025 | -1457% | -193 points |
| Q4 2024 | -885% | +82 points |
ABUS's operating margin was −3510% last quarter, down 1873 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ABUS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ABUS on profitability, with a higher operating margin.
ABUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $239.8M | +$245.6M |
| Q2 2026 | -$6M | +$9.7M |
| Q1 2026 | -$8.1M | +$5.3M |
| Q4 2025 | -$4.7M | +$5.7M |
| Q3 2025 | -$5.8M | +$14.9M |
| Q2 2025 | -$15.7M | -$1.2M |
| Q1 2025 | -$13.4M | +$6M |
| Q4 2024 | -$10.4M | +$6.9M |
ABUS's free cash flow has turned positive after six years mostly in the red: $221M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ABUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +2.2M shares |
| 1 year | +4.1% | +7.8M shares |
| 3 years | +19% | +32.1M shares |
| 5 years | +106% | +103M shares |
| Available history | +190% | +131M shares |
ABUS has 200M diluted shares, up 4.1% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ABUS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ABUS Net Leverage
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ABUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.0 | Neutral |
| Stochastic | 12.4 | Oversold |
ABUS's weekly RSI is 42 (neutral) and its Stochastic is 12 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ABUS PE vs Healthcare Sector
| Metric | ABUS | Sector median | Relative |
|---|---|---|---|
| PE | 3.6x | 26x | 86% below |
| PE % | 0 | 29 | 29 pts below |
ABUS is trading at 3.6x earnings, a 86% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ABUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.23 | 4.7% below |
| 20 week MA | $4.58 | 12% below |
| 50 week MA | $4.45 | 9.4% below |
| 100 week MA | $4.03 | 0% above |
| 200 week MA | $3.43 | 17% above |
ABUS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ABUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.49 | $3.87 | +55% |
| 2021 | $3.87 | $4.16 | +7.5% |
| 2022 | $4.16 | $2.39 | -43% |
| 2023 | $2.39 | $2.50 | +4.6% |
| 2024 | $2.50 | $3.21 | +28% |
| 2025 | $3.21 | $4.78 | +49% |
| 2026 YTD | $4.78 | $4.03 | -16% |
ABUS has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.